Clinical Trials

Inclusion Criteria: 

• Age ≥ 18 years old.
• Histologically or cytologically documented NSCLC with resectable (Stage IIA to select [ie, N2] Stage IIIB) disease. 
• World Health Organization (WHO)/ECOG PS of 0 or 1 at enrollment. 
• At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 Target Lesion (TL) at baseline. 
• No prior exposure to immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anticancer vaccines.
• Adequate organ and marrow function.
• Confirmation of a patients tumour PD-L1 status.
• Documented EGFR and ALK status.

Exclusion Criteria: 

• History of allogeneic organ transplantation. 
• Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease, diverticulitis, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome).
• History of another primary malignancy.
• History of active primary immunodeficiency.
• Active infection including tuberculosis hepatitis B, or human immunodeficiency virus.
• Deemed unresectable NSCLC by multidisciplinary evaluation. 
• Patients who have pre-operative radiotherapy treatment as part of their care plan. 
• Patients who have brain metastases or spinal cord compression. 
• Stage IIIB N3 and Stages IIIC, IVA, and IVB NSCLC. 
• Mixed small cell and NSCLC histology. 
• Patients who are candidates to undergo only segmentectomies or wedge resections.